RxDoctor Payments Data

Bradley Schwartz, MD

Urology · Springfield, ILNPI 1821084856

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $27,635 of the $44,742 with a category attached, or 61.8%. Cook Incorporated accounts for 76.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2020 at $11,486 and has fallen 77.4% since, to $2,597 in 2025. Among urology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$44,742in general payments, 2019–2025

Across 99 payments — averaging $451.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Incorporated$34K
  • C. R. Bard, Inc. & Subsidiaries$4K
  • Cook Medical LLC$2K
  • Intuitive Surgical$2K
  • Cook Research Incorporated$1K
  • Olympus America Inc.$367
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$11,06025%
  • Speaking & faculty fees$27,63562%
  • Travel & lodging$1,9044%
  • Food & beverage$4,0439%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,742 in reported general payments places this provider in the 90th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$135,721
Medicare patients
272
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron52$30,954
GemtesaVibegron27$12,969
Potassium Citrate ErPotassium Citrate62$10,551
Tamsulosin Hcl254$3,345
Solifenacin Succinate30$1,518
Alfuzosin Hcl ErAlfuzosin Hcl20$1,029
Finasteride81$855
Oxybutynin Chloride ErOxybutynin Chloride16$527
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$315
Allopurinol78$303
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen50$297
Indapamide16$218
Ciprofloxacin Hcl15$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$114$30,95452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 550 urology providers in Illinois.

Other urology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →